COVID-19：中国灭活疫苗，对 Omicron 菌株的效果较差：自然

COVID-19：中国灭活疫苗，对 Omicron 菌株的效果较差：自然

英文学术期刊《自然》：

1 月 13 日的文章：

“中国开发的灭活疫苗对Omicron毒株的效果较差，”他说。

作为疫苗外交的一部分，中国正在向发展中国家提供灭活疫苗。

然而，他说，“对中国疫苗的重新评估是不可避免的。”

针对 Omicron 菌株的中和抗体：

25人两次接种了中国科兴新冠疫苗。

作为血液分析的结果

“没有检测到针对 Omicron 菌株的中和抗体，”他说。

香港大学：

香港大学的一个研究小组引用了去年 12 月发表的一篇论文。

灭活疫苗无效：

“在许多实验中，灭活疫苗对 Omicron 菌株不是很有效，”他说。

第三次接种效果：

即使第三次接种灭活疫苗，
与其他疫苗相比
还显示效果显着降低。
接种灭活疫苗的中和抗体数量非常少。

“给一组患者接种三剂灭活疫苗并没有改善，”他说。

信使 RNA 疫苗
重组蛋白疫苗

另一方面，

西方制造的信使RNA，
用于重组蛋白疫苗等。
显示了“第三次接种对 Omicron 菌株的显着影响”。

大自然的主张：

根据这项实验的结果，Nature 敦促重新评估灭活疫苗的作用。

大纪元

https://www.epochtimes.jp/2022/01/85132.html

Omicron thwarts some of the world’s most-used COVID vaccines

The world’s most widely used COVID-19 vaccines provide little to no protection against infection with the rapidly spreading Omicron variant, laboratory evidence suggests.

Inactivated-virus vaccines
contain SARS-CoV-2 particles that have been chemically treated to make it impossible for them to cause an infection.

Stable and relatively easy to manufacture,

such vaccines have been distributed widely as part of China’s global vaccine diplomacy, helping them to become the jab of choice in many countries.

But a multitude of experiments show that they are consistently hobbled by Omicron.

Many people who receive two jabs of an inactivated vaccine fail to produce immune molecules that can counter Omicron transmission.

And even after a third dose of an inactivated vaccine, an individual’s levels of ‘neutralizing’ antibodies,

which provide a potent safeguard against viral infection of cells, tend to remain low.

A third shot of another type of vaccine, such as those based on messenger RNA or purified proteins,

seems to offer better protection against Omicron.

The findings are prompting many scientists and public-health researchers

to re-evaluate the role of inactivated vaccines in the global fight against COVID-19.

“At this stage, we have to evolve our ideas and adjust our vaccination strategies,” says Qiang Pan-Hammarström,

a clinical immunologist at the Karolinska Institute in Stockholm.

Billions served

Inactivated vaccines
were instrumental in the campaign for worldwide vaccine coverage last year.

They include those made by China’s Sinovac and Sinopharm,
which together account for nearly 5 billion of the more than 11 billion COVID-19 vaccine doses delivered globally so far,

according to numbers compiled by data-tracking firm Airfinity in London (see ‘Many shields against COVID-19’).

More than 200 million doses of other inactivated shots such as

India’s Covaxin,
Iran’s COVIran Barekat and Kazakhstan’s QazVac

have also been delivered.

But an early sign that
inactivated vaccines might not hold up to Omicron came in December,

when researchers in Hong Kong analysed blood from 25 recipients of the two-dose CoronaVac vaccine,

made by the Beijing-based company Sinovac.

Not a single person had detectable neutralizing antibodies against the new variant

— raising the possibility that all the participants were highly vulnerable to Omicron infection1.

https://www.nature.com/articles/d41586-022-00079-6